Sankyo Articles
MIGRAINE MARKET SET TO BLOSSOM
21 February 1994
TOKYO STOCK COMMENT
14 February 1994
JAPANESE DRUG REIMBURSEMENT CUTS
14 February 1994
TOKYO STOCK COMMENT
7 February 1994
TOKYO STOCK COMMENT
31 January 1994
SANKYO, NBI IN CROSS LICENSING DEAL
31 January 1994
WINNERS AND LOSERS IN GLOBAL PHARMA INDUSTRY
31 January 1994
SANKYO LAUNCH
24 January 1994
GLAXO'S ZOFRAN APPROVED IN JAPAN
24 January 1994
TOKYO STOCK COMMENT
24 January 1994
WORLD HEMATOLOGY MARKET FORECASTS
24 January 1994
TOKYO STOCK COMMENT
17 January 1994
TOKYO STOCK COMMENT
10 January 1994
MILES-SANKYO MERGES DIAGNOSTIC ARM
10 January 1994
SANKYO FOCUSES EFFORTS ON NSAID
10 January 1994
SANKYO-DEVELOPED DRUGS SPUR GROWTH
10 January 1994
COST-CUTTING IS BOOSTING JAPANESE PHARMA EARNINGS
10 January 1994
TOKYO STOCK COMMENT
20 December 1993
JAPAN TO LOWER IFN, HYPOLIPEMIC PRICES
20 December 1993
MUSCULOSKELETAL MARKET TO DECLINE
6 December 1993
TOKYO STOCK COMMENT
29 November 1993
TOKYO STOCK COMMENT
22 November 1993
TOKYO STOCK COMMENT
15 November 1993
TOKYO STOCK COMMENT
8 November 1993
TOKYO STOCK COMMENT
1 November 1993
TOKYO STOCK COMMENT
25 October 1993
TOKYO STOCK COMMENT
25 October 1993
ASIA-PACIFIC DRUG MARKETS' POTENTIAL
25 October 1993
WORLD CARDIO-DRUGS MARKET
25 October 1993
TOKYO STOCK COMMENT
11 October 1993
TOKYO STOCK COMMENT
4 October 1993
TOKYO STOCK COMMENT
13 September 1993
TOKYO STOCK COMMENT
6 September 1993
TOKYO STOCK COMMENT
23 August 1993
TOKYO STOCK COMMENT
16 August 1993
TOKYO STOCK COMMENT
9 August 1993
TOKYO STOCK COMMENT
2 August 1993
JAPAN DRUGMAKERS' FOREIGN SALES STILL LOW
26 July 1993
TOKYO STOCK COMMENT
28 June 1993
COMPETITIVE DYNAMICS IN PHARMA INDUSTRY
28 June 1993
US VS JAPANESESTOCK MARKETS
21 June 1993
EUROPE STOCK COMMENT
24 May 1993
TOKYO STOCK COMMENT
10 May 1993
EUROPE STOCK COMMENT
26 April 1993
TOKYO STOCK COMMENT
19 April 1993
TOKYO STOCK COMMENT
12 April 1993
PRICE FLEXIBILITY AND THE DRUG INDUSTRY
12 April 1993
SANKYO ANTI-HIV AGENT
29 March 1993
TOKYO STOCK COMMENT
29 March 1993
TOKYO STOCK COMMENT
22 March 1993
TOKYO STOCK COMMENT
15 March 1993
PHARMACEUTICAL DESIGN: EPITOPE SELECTION
15 March 1993
SANKYO LAUNCHES NEW PRODUCTS
8 March 1993
TOKYO STOCK COMMENT
8 March 1993
TOKYO STOCK COMMENT
1 March 1993
TOKYO STOCK COMMENT
22 February 1993
TOKYO STOCK COMMENT
15 February 1993
JAPANESE MEETING YIELDS NEW COMPOUNDS
8 February 1993
WORLD ANTICANCER/ IMMUNOLOGY MARKET
8 February 1993
TOKYO STOCK COMMENT
1 February 1993
GLAXO TO FILE FOR OTC ZANTAC IN 1994?
1 February 1993
TOKYO STOCK COMMENT
4 January 1993
JAPANESE DIABETES DRUGS IN DEVELOPMENT
4 January 1993
GLOBAL DRUG MARKET: 30 YEARS OF GROWTH
4 January 1993
TOKYO STOCK COMMENT
21 December 1992
TOKYO STOCK COMMENT
14 December 1992
TOKYO STOCK COMMENT
9 November 1992
STOCK MARKET COMMENTARY: TOKYO
12 October 1992
SANYO-KOKUSAKU GOES INTO AIDS R&D
12 October 1992
TOKYO STOCK COMMENT
7 September 1992
TOKYO STOCK COMMENT
3 August 1992
JAPANESE FIRMS' R&D SPENDING IS RISING
6 July 1992
Tokyo Stock Comment
29 June 1992
JAPANESE INDUSTRY'S MOVE WESTWARDS
29 June 1992
Tokyo stock comment
22 June 1992
Tokyo: Stock Commentary
8 June 1992
good year for Sankyo
1 June 1992
Stock Commentary: Tokyo
1 June 1992
STOCK MARKET COMMENTARY:TOKYO
25 May 1992
SANDOZ PHARMA DIV 1991 PROGRESS
25 May 1992
STOCK MARKET COMMENTARY: TOKYO
18 May 1992
NO BIG FOREIGN DRUG BUYS BY JAPANESE FIRMS
18 May 1992
JAPAN SUBSIDS DO WELL FOR MNCs
18 May 1992
STOCK MARKET COMMENTARY: TOKYO
4 May 1992
WARNER-LAMBERT'S VIEW TO THE FUTURE
27 April 1992
STOCK MARKET COMMENTARY: TOKYO
27 April 1992
STOCK MARKET COMMENTARY: TOKYO
13 April 1992
STOCK MARKET COMMENTARY: TOKYO
6 April 1992
STOCK MARKET COMMENTARY: TOKYO
6 April 1992
STOCK MARKET COMMENTARY: TOKYO
23 March 1992
STOCK MARKET COMMENTARY: TOKYO
16 March 1992
STOCK MARKET COMMENTARY: TOKYO
10 February 1992
STOCK MARKET COMMENTARY: TOKYO
3 February 1992
JAPANESE YEAR-END APPROVALS
27 January 1992
STOCK MARKET COMMENTARY: TOKYO
27 January 1992
BANYU PINS HOPESON LIPOVAS
20 January 1992
JAPANESE DRUG FIRMS IN EUROPE: FT STUDY
13 January 1992
STOCK MARKET COMMENTARY: TOKYO
13 January 1992
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
